Skin sterol identifies multivessel disease risk
This article was originally published in Clinica
Executive Summary
Measurements from IMI International Medical Innovations' noninvasive, point-of-care skin sterol test, PREVU, when combined with a patient's cardiac disease risk as classified by the Framingham global risk score, could pinpoint patients with a higher risk of multivessel disease - ie narrowing in two or more coronary vessels. So revealed a 649-patient study that found that when skin sterol and Framingham risk were both elevated, the likelihood of multivessel disease was four times greater. Toronto, Canada-based IMI has already received clearance to sell PREVU in the US, Canada and Europe for assessing coronary artery disease risk. In a separate announcement, the firm said it was launching a 78-patient pivotal clinical study of its non-invasive breast cancer detection test, which identifies a cancer-associated sugar in nipple-aspirate fluid.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.